In one of the earlier studies that proved the feasibility of detecting DNA-methylation markers in CCA, a four-gene panel with HOXA1, PKRCB, CYP26C1, and PTGDR was proposed to differentiate CCA from healthy controls with sensitivity/specificity of 83%/93% (76). The gene discussed is HOXA1; the disease is cholangiocarcinoma.